Related Experiment Videos
Cefazolin in the treatment of pneumonia
Abstract:
Cefazolin is a semi-synthetic derivative of cephalosporin C that has a lower cross-immunogenicity with penicillins than do the other cephalosporins. This agent was evaluated as an alternative to penicillin in the therapy of patients with pneumococcal pneumonia. Thirty patient were treated with cefazolin, most receiving 125 or 250 mg IM every 12 hours for 5-10 days. Satisfactory clinical responses were obtained in 29 of these 30 patients, and none complained of pain following IM injections. Three patients developed eosinophilia while receiving cefazolin, and one of these also had a maculopapular eruption that may have been an allergic reaction to cefazolin. Serum levels of cefazolin were measured at 1, 6, and 12 hours after administration. Susceptibilities of 100 isolates of Streptococcus pneumoniae, including these patients' organisms, were determined by broth dilution. Both cefazolin and cephalothin were bactericidal for all 100 isolates at concentrations of 2 microgram/ml or less. Cefazolin appears to be an entirely adequate alternative to penicillin for the therapy of pneumococcalpneumonia. This agent is effective in low dosages, and adequate serum levels are maintained for long periods of time, permitting twice-daily administration.
Insights
Cefazolin effectively treats pneumococcal pneumonia in adults, offering a safe alternative to penicillin. This antibiotic demonstrates efficacy in low doses with minimal injection site pain and good serum level maintenance.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Pneumococcal pneumonia remains a significant public health concern.
- Penicillin has been the standard treatment, but concerns about allergies and resistance exist.
- Cefazolin, a cephalosporin antibiotic, offers potential as an alternative due to lower cross-reactivity with penicillin.
Purpose of the Study:
- To evaluate cefazolin as an alternative therapy for pneumococcal pneumonia.
- To assess the clinical efficacy and safety of cefazolin in patients with pneumococcal pneumonia.
- To determine appropriate dosing and administration intervals for cefazolin in this patient population.
Main Methods:
- A clinical trial involving 30 patients with pneumococcal pneumonia treated with cefazolin.
- Dosages administered were typically 125 or 250 mg intramuscularly every 12 hours for 5-10 days.
- Serum levels of cefazolin were monitored, and in vitro susceptibility testing of Streptococcus pneumoniae isolates was performed.
Main Results:
- 29 out of 30 patients showed satisfactory clinical responses to cefazolin.
- No patients reported pain at injection sites.
- Cefazolin demonstrated bactericidal activity against all tested Streptococcus pneumoniae isolates at low concentrations.
Conclusions:
- Cefazolin is an effective and well-tolerated alternative to penicillin for treating pneumococcal pneumonia.
- Low-dose cefazolin therapy provides adequate serum levels for twice-daily administration.
- Further investigation into potential allergic reactions, such as eosinophilia and rash, is warranted.